|
1
|
Liu S, Cao Q, An G, Yan B and Lei L:
Identification of the 3-lncRNA signature as a prognostic biomarker
for colorectal cancer. Int J Mol Sci. 21:93592020. View Article : Google Scholar
|
|
2
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar
|
|
3
|
Wilkins T, McMechan D and Talukder A:
Colorectal cancer screening and prevention. Am Fam Physician.
97:658–665. 2018.PubMed/NCBI
|
|
4
|
Salibasic M, Pusina S, Bicakcic E, Pasic
A, Gavric I, Kulovic E, Rovcanin A and Beslija S: Colorectal cancer
surgical treatment, our experience. Med Arch. 73:412–414. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koi M and Carethers JM: The colorectal
cancer immune microenvironment and approach to immunotherapies.
Future Oncol. 13:1633–1647. 2017. View Article : Google Scholar
|
|
6
|
Nozawa H, Sonoda H, Ishii H, Emoto S,
Murono K, Kaneko M, Sasaki K, Nishikawa T, Shuno Y, Tanaka T, et
al: Postoperative chemotherapy is associated with prognosis of
stage IV colorectal cancer treated with preoperative
chemotherapy/chemoradiotherapy and curative resection. Int J
Colorectal Dis. 35:177–180. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang GR, Wang ZW and Jin ZY: Application
and progress of texture analysis in the therapeutic effect
prediction and prognosis of neoadjuvant chemoradiotherapy for
colorectal cancer. Chin Med Sci J. 34:45–50. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang F, Zhang Y, Zhao W, Deng K, Wang Z,
Yang C, Ma L, Openkova MS, Hou Y and Li K: Metabolomics for
biomarker discovery in the diagnosis, prognosis, survival and
recurrence of colorectal cancer: A systematic review. Oncotarget.
8:35460–35472. 2017. View Article : Google Scholar
|
|
9
|
Jin M and Frankel WL: Lymph node
metastasis in colorectal cancer. Surg Oncol Clin N Am. 27:401–412.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ijsselsteijn R, Jansen JG and de Wind N:
DNA mismatch repair-dependent DNA damage responses and cancer. DNA
Repair (Amst). 93:1029232020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Konishi T, Shimada Y, Hsu M, Tufts L,
Jimenez-Rodriguez R, Cercek A, Yaeger R, Saltz L, Smith JJ, Nash
GM, et al: Association of preoperative and postoperative serum
carcinoembryonic antigen and colon cancer outcome. JAMA Oncol.
4:309–315. 2018. View Article : Google Scholar
|
|
12
|
Das V, Kalita J and Pal M: Predictive and
prognostic biomarkers in colorectal cancer: A systematic review of
recent advances and challenges. Biomed Pharmacother. 87:8–19. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Y and Wang X: PLK4: A promising
target for cancer therapy. J Cancer Res Clin Oncol. 145:2413–2422.
2019. View Article : Google Scholar
|
|
14
|
Maniswami RR, Prashanth S, Karanth AV,
Koushik S, Govindaraj H, Mullangi R, Rajagopal S and Jegatheesan
SK: PLK4: A link between centriole biogenesis and cancer. Expert
Opin Ther Targets. 22:59–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Godinho SA, Picone R, Burute M, Dagher R,
Su Y, Leung CT, Polyak K, Brugge JS, Théry M and Pellman D:
Oncogene-like induction of cellular invasion from centrosome
amplification. Nature. 510:167–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim DH, Ahn JS, Han HJ, Kim HM, Hwang J,
Lee KH, Cha-Molstad H, Ryoo IJ, Jang JH, Ko SK, et al: Cep131
overexpression promotes centrosome amplification and colon cancer
progression by regulating Plk4 stability. Cell Death Dis.
10:5702019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liao Z, Zhang H, Fan P, Huang Q, Dong K,
Qi Y, Song J, Chen L, Liang H, Chen X, et al: High PLK4 expression
promotes tumor progression and induces epithelialmesenchymal
transition by regulating the Wnt/β-catenin signaling pathway in
colorectal cancer. Int J Oncol. 54:479–490. 2019. View Article : Google Scholar
|
|
18
|
Meng L, Zhou Y, Ju S, Han J, Song C, Kong
J, Wu Y, Lu S, Xu J, Yuan W, et al: A cis-eQTL genetic variant in
PLK4 confers high risk of hepatocellular carcinoma. Cancer Med.
8:6476–6484. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Z, Sun H, Ma W, Wu K, Peng G, Ou T
and Wu S: Down-regulation of Polo-like kinase 4 (PLK4) induces G1
arrest via activation of the p38/p53/p21 signaling pathway in
bladder cancer. FEBS Open Bio. 11:2631–2646. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He Y, Wang H, Yan M, Yang X, Shen R, Ni X,
Chen X, Yang P, Chen M, Lu X, et al: High LIN28A and PLK4
coexpression is associated with poor prognosis in epithelial
ovarian cancer. Mol Med Rep. 18:5327–5336. 2018.PubMed/NCBI
|
|
21
|
Pu JT, Hu Z, Zhang DG, Zhang T, He KM and
Dai TY: MiR-654-3p suppresses non-small cell lung cancer
tumourigenesis by inhibiting PLK4. Onco Targets Ther. 13:7997–8008.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang N, Liu FL, Ma TS and Zhang ZZJ:
LncRNA SNHG1 contributes to tumorigenesis and mechanism by
targeting miR-338-3p to regulate PLK4 in human neuroblastoma. Eur
Rev Med Pharmacol Sci. 23:8971–8983. 2019.
|
|
23
|
Zhou Q, Fan G and Dong Y: Polo-like kinase
4 correlates with greater tumor size, lymph node metastasis and
confers poor survival in non-small cell lung cancer. J Clin Lab
Anal. 34:e231522020. View Article : Google Scholar
|
|
24
|
Hu Z, Gu X, Zhong R and Zhong H:
Tumor-infiltrating CD45RO+ memory cells correlate with
favorable prognosis in patients with lung adenocarcinoma. J Thorac
Dis. 10:2089–2099. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Z, Dai K, Wang C, Song Y, Gu F, Liu F
and Fu L: Expression of polo-like kinase 4(PLK4) in breast cancer
and its response to taxane-based neoadjuvant chemotherapy. J
Cancer. 7:1125–1132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fohlen A, Bordji K, Assenat E, Gongora C,
Bazille C, Boulonnais J, Naveau M, Breuil C, Pérès EA, Bernaudin M
and Guiu B: Anticancer drugs for intra-arterial treatment of
colorectal cancer liver metastases: In-vitro screening after short
exposure time. Pharmaceuticals (Basel). 14:6392021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J, Mo R and Zheng L: MicroRNA-490-3p
inhibits migration and chemoresistance of colorectal cancer cells
via targeting TNKS2. World J Surg Oncol. 19:1172021. View Article : Google Scholar
|
|
29
|
Liu X: Targeting polo-like kinases: A
promising therapeutic approach for cancer treatment. Transl Oncol.
8:185–195. 2015. View Article : Google Scholar
|
|
30
|
Parsyan A, Cruickshank J, Hodgson K,
Wakeham D, Pellizzari S, Bhat V and Cescon DW: Anticancer effects
of radiation therapy combined with polo-like kinase 4 (PLK4)
inhibitor CFI-400945 in triple negative breast cancer. Breast.
58:6–9. 2021. View Article : Google Scholar
|
|
31
|
Zhang X, Wei C, Liang H and Han L:
Polo-like kinase 4′s critical role in cancer development and
strategies for Plk4-targeted therapy. Front Oncol. 11:5875542021.
View Article : Google Scholar
|
|
32
|
Garvey DR, Chhabra G, Ndiaye MA and Ahmad
N: Role of polo-like kinase 4 (PLK4) in epithelial cancers and
recent progress in its small molecule targeting for cancer
management. Mol Cancer Ther. 20:632–640. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Zuo J, Wang M, Ma X, Gao K, Bai X,
Wang N, Xie W and Liu H: Pololike kinase 4 promotes tumorigenesis
and induces resistance to radiotherapy in glioblastoma. Oncol Rep.
41:2159–2167. 2019.PubMed/NCBI
|
|
34
|
Bao J, Yu Y, Chen J, He Y, Chen X, Ren Z,
Xue C, Liu L, Hu Q, Li J, et al: MiR-126 negatively regulates PLK-4
to impact the development of hepatocellular carcinoma via ATR/CHEK1
pathway. Cell Death Dis. 9:10452018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kazazian K, Go C, Wu H, Brashavitskaya O,
Xu R, Dennis JW, Gingras AC and Swallow CJ: Plk4 promotes cancer
invasion and metastasis through Arp2/3 complex regulation of the
actin cytoskeleton. Cancer Res. 77:434–447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yeung SF, Zhou Y, Zou W, Chan WL and Ching
YP: TEC kinase stabilizes PLK4 to promote liver cancer metastasis.
Cancer Lett. 524:70–81. 2021. View Article : Google Scholar
|
|
37
|
Zhu Y, Liu Z, Qu Y, Zeng J, Yang M, Li X,
Wang Z, Su J, Wang X, Yu L and Wang Y: YLZ-F5, a novel polo-like
kinase 4 inhibitor, inhibits human ovarian cancer cell growth by
inducing apoptosis and mitotic defects. Cancer Chemother Pharmacol.
86:33–43. 2020. View Article : Google Scholar
|
|
38
|
Marina M and Saavedra HI: Nek2 and Plk4:
Prognostic markers, drivers of breast tumorigenesis and drug
resistance. Front Biosci (Landmark Ed). 19:352–365. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sredni ST, Bailey AW, Suri A, Hashizume R,
He X, Louis N, Gokirmak T, Piper DR, Watterson DM and Tomita T:
Inhibition of polo-like kinase 4 (PLK4): A new therapeutic option
for rhabdoid tumors and pediatric medulloblastoma. Oncotarget.
8:111190–111212. 2017. View Article : Google Scholar
|
|
40
|
Zhang Z, Wang Z, Huang K, Liu Y, Wei C,
Zhou J, Zhang W, Wang Q, Liang H, Zhang A, et al: PLK4 is a
determinant of temozolomide sensitivity through phosphorylation of
IKBKE in glioblastoma. Cancer Lett. 443:91–107. 2019. View Article : Google Scholar
|
|
41
|
Zhang Y, Kang M, Zhang B, Meng F, Song J,
Kaneko H, Shimamoto F and Tang B: m6A
modification-mediated CBX8 induction regulates stemness and
chemosensitivity of colon cancer via upregulation of LGR5. Mol
Cancer. 18:1852019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang J, Miller Z, Musich PR, Thomas AE,
Yao ZQ, Xie Q, Howe PH and Jiang Y: DSTYK promotes metastasis and
chemoresistance via EMT in colorectal cancer. Front Pharmacol.
11:12502020. View Article : Google Scholar
|
